FDA's $250K Singapore Trip During Government Shutdown Sparks Controversy

FDA Under Scrutiny

• ⚠️ The FDA is facing multiple criticisms, including controversial staff appointments, significant staffing cuts, and public questioning of its medical policies by former chiefs.
• ✈️ Amidst a government shutdown, the FDA approved a quarter-of-a-million-dollar trip for 31 staffers to attend a conference in Singapore.

Conference Details and Timing

• 🗓️ The trip, costing over $8,000 per person, was approved on November 12th, just before the House voted to end the government shutdown.
• 🏨 The conference, the International Council for Harmonization (ICH), took place at a luxury hotel on Sentosa island, known for its theme park and casino.
• 🎯 The ICH conference aims to unify global standards for drug development and approval.

Agency Context and Funding

• 📉 The FDA has experienced a roughly 15% reduction in staff, with proposed further budget cuts from the Trump administration.
• 💰 The $250,000 trip was funded by carryover user fees collected from medical product manufacturers, not taxpayer dollars directly allocated for the shutdown period.

Public Perception and Response

• 🗣️ A watchdog group highlighted the poor public perception of international travel during a shutdown, emphasizing the need for agency resourcing.
• 🌐 An FDA spokesperson stated the meeting was mission-critical and essential for global alignment on regulatory science, noting similar attendance in prior years.
• 🔍 The FDA appeared aware of the optics, with internal documents noting that conference approvals during a shutdown would be handled on a case-by-case basis by senior leadership.
• 🔗 Shortly after CNBC's inquiry, the FDA removed website links detailing its travel policies during a government shutdown, stating routine updates.

Broader Implications

• ❓ Questions remain about whether the conference attendance aligns with the intended use of shutdown-period funding, which is primarily for imminent threats.
• 📈 This incident adds to ongoing concerns about the FDA's spending, management, and revolving door of top staff, as noted by Congressman James Comer.